These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000944-26 A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance i... not-yet-due
Ongoing 2005-000309-75 A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab not-yet-due
Ongoing 2005-003796-20 Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission foll... not-yet-due
Not reported 2005-003839-41 Imatinib in combination with Cytarabine as compared to Imatinib alone in patients with first chronic phase Chronic Myeloid Leukemia. 2013-10-01 due-trials
Completed, but no date 2005-003891-39 Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to... bad-data
Ongoing 2006-001777-19 A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years. not-yet-due
Ongoing 2006-002141-37 Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell ... not-yet-due
Ongoing 2006-005174-42 Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in elderly patients (66-80 years) with d... not-yet-due
Ongoing 2006-007083-28 Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial o... not-yet-due
Ongoing 2007-002533-37 Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma not-yet-due
Ongoing 2007-004007-34 Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-... not-yet-due
Ongoing 2007-005487-28 Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CLL not-yet-due
Completed, but no date 2008-000404-92 Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (A... bad-data
Ongoing 2008-001290-15 Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase III... not-yet-due
Ongoing 2008-002195-10 A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk mye... not-yet-due
Ongoing 2008-003540-11 Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase I... not-yet-due
Ongoing 2008-005798-36 Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. not-yet-due
Ongoing 2009-011613-24 Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously unt... not-yet-due
Ongoing 2009-013094-17 A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and v... not-yet-due
Ongoing 2009-014455-68 A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ver... not-yet-due
Ongoing 2009-014722-42 Rituximab in Primary Central Nervous system Lymphoma. not-yet-due
Ongoing 2009-017903-28 A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide mainte... not-yet-due
Other 2010-018494-37 A randomized phase II study for evaluation of T cell depleted non myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bor... not-yet-due
Ongoing 2010-021445-42 A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amylo... not-yet-due
Ongoing 2010-023436-16 The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study. not-yet-due
Ongoing 2011-000097-56 ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study. not-yet-due
Ongoing 2011-003237-33 Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. not-yet-due
Ongoing 2012-001188-55 Double umbilical cord blood transplantation in high-risk hematological patients. not-yet-due
Ongoing 2012-003344-74 A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with po... not-yet-due
Ongoing 2012-004915-30 Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study. not-yet-due
Ongoing 2013-000320-33 Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV) not-yet-due
Ongoing 2013-000432-10 A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIEN... not-yet-due
Ongoing 2013-002711-94 HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia. not-yet-due
Ongoing 2013-002843-26 Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients age... not-yet-due
Ongoing 2013-003265-34 Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multipl... not-yet-due
Ongoing 2013-003266-14 Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous ... not-yet-due
Ongoing 2013-004394-27 Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma not-yet-due
Ongoing 2013-005157-75 Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients not-yet-due
Ongoing 2014-001363-12 autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial not-yet-due
Ongoing 2014-001876-75 A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk... not-yet-due
Ongoing 2014-002654-39 A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U not-yet-due
Ongoing 2015-000195-98 A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transpl... not-yet-due
Ongoing 2015-002855-85 A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPS... not-yet-due
Ongoing 2015-004985-27 A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followe... not-yet-due
Ongoing 2016-001211-21 Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first ... not-yet-due
Ongoing 2016-002599-29 A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or ... not-yet-due
Ongoing 2016-002600-90 Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and fra... not-yet-due
Ongoing 2016-003105-33 Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients not-yet-due
Ongoing 2017-000555-10 Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study. not-yet-due
Ongoing 2017-000766-30 Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. not-yet-due
Ongoing 2017-002335-42 A phase I/II feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with FLT3-ITD AML not-yet-due